{"id":31312,"date":"2023-02-01T17:47:31","date_gmt":"2023-02-01T16:47:31","guid":{"rendered":"https:\/\/archivio.irpa.eu\/articolo\/il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse\/"},"modified":"2023-02-01T17:48:49","modified_gmt":"2023-02-01T16:48:49","slug":"il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse","status":"publish","type":"journal_article","link":"https:\/\/archivio.irpa.eu\/en\/article\/il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse\/","title":{"rendered":"The pharmaceutical payback. The balancing of interests facing resource scarcity"},"content":{"rendered":"

The pharmaceutical \u00abpayback\u00bb mechanism is complex, given the multiple public and private interests involved. Indeed, as conceived, it allows for balancing the public spending restraint (Article 81 of the Constitution) and citizens\u2019 right to health (art. 32 Cost). However, the mechanism has several problematic aspects that can prejudice companies and consequently increase litigation. Considering the recent judgments of the Lazio Regional Administrative Tribunal, this paper aims to analyse the pharmaceutical payback mechanism by highlighting its peculiarities and critical issues, ultimately to reflect on a possible replacement. However, to date, as will be discussed, such a substitution appears to be difficult given the need to ensure the sustainability of pharmaceutical spending and, therefore, access to medicines.<\/p>\n","protected":false},"excerpt":{"rendered":"

The pharmaceutical \u00abpayback\u00bb mechanism is complex, given the multiple public and private interests involved. Indeed, as conceived, it allows for balancing the public spending restraint (Article 81 of the Constitution) and citizens\u2019 right to health (art. 32 Cost). However, the mechanism has several problematic aspects that can prejudice companies and consequently increase litigation. Considering the<\/p>\n","protected":false},"template":"","acf":[],"yoast_head":"\nThe pharmaceutical payback. The balancing of interests facing resource scarcity - IRPA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/archivio.irpa.eu\/en\/article\/il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The pharmaceutical payback. The balancing of interests facing resource scarcity - IRPA\" \/>\n<meta property=\"og:description\" content=\"The pharmaceutical \u00abpayback\u00bb mechanism is complex, given the multiple public and private interests involved. Indeed, as conceived, it allows for balancing the public spending restraint (Article 81 of the Constitution) and citizens\u2019 right to health (art. 32 Cost). However, the mechanism has several problematic aspects that can prejudice companies and consequently increase litigation. Considering the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/archivio.irpa.eu\/en\/article\/il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse\/\" \/>\n<meta property=\"og:site_name\" content=\"IRPA\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-01T16:48:49+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/archivio.irpa.eu\/en\/article\/il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse\/\",\"url\":\"https:\/\/archivio.irpa.eu\/en\/article\/il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse\/\",\"name\":\"The pharmaceutical payback. The balancing of interests facing resource scarcity - IRPA\",\"isPartOf\":{\"@id\":\"https:\/\/archivio.irpa.eu\/en\/#website\"},\"datePublished\":\"2023-02-01T16:47:31+00:00\",\"dateModified\":\"2023-02-01T16:48:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/archivio.irpa.eu\/en\/article\/il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/archivio.irpa.eu\/en\/article\/il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/archivio.irpa.eu\/en\/article\/il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/archivio.irpa.eu\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The pharmaceutical payback. The balancing of interests facing resource scarcity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/archivio.irpa.eu\/en\/#website\",\"url\":\"https:\/\/archivio.irpa.eu\/en\/\",\"name\":\"IRPA\",\"description\":\"Istituto di Ricerca sulla Pubblica Amministrazione\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/archivio.irpa.eu\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The pharmaceutical payback. The balancing of interests facing resource scarcity - IRPA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/archivio.irpa.eu\/en\/article\/il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse\/","og_locale":"en_US","og_type":"article","og_title":"The pharmaceutical payback. The balancing of interests facing resource scarcity - IRPA","og_description":"The pharmaceutical \u00abpayback\u00bb mechanism is complex, given the multiple public and private interests involved. Indeed, as conceived, it allows for balancing the public spending restraint (Article 81 of the Constitution) and citizens\u2019 right to health (art. 32 Cost). However, the mechanism has several problematic aspects that can prejudice companies and consequently increase litigation. Considering the","og_url":"https:\/\/archivio.irpa.eu\/en\/article\/il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse\/","og_site_name":"IRPA","article_modified_time":"2023-02-01T16:48:49+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/archivio.irpa.eu\/en\/article\/il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse\/","url":"https:\/\/archivio.irpa.eu\/en\/article\/il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse\/","name":"The pharmaceutical payback. The balancing of interests facing resource scarcity - IRPA","isPartOf":{"@id":"https:\/\/archivio.irpa.eu\/en\/#website"},"datePublished":"2023-02-01T16:47:31+00:00","dateModified":"2023-02-01T16:48:49+00:00","breadcrumb":{"@id":"https:\/\/archivio.irpa.eu\/en\/article\/il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/archivio.irpa.eu\/en\/article\/il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/archivio.irpa.eu\/en\/article\/il-payback-farmaceutico-il-contemperamento-di-interessi-a-fronte-della-scarsita-di-risorse\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/archivio.irpa.eu\/en\/"},{"@type":"ListItem","position":2,"name":"The pharmaceutical payback. The balancing of interests facing resource scarcity"}]},{"@type":"WebSite","@id":"https:\/\/archivio.irpa.eu\/en\/#website","url":"https:\/\/archivio.irpa.eu\/en\/","name":"IRPA","description":"Istituto di Ricerca sulla Pubblica Amministrazione","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/archivio.irpa.eu\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/archivio.irpa.eu\/en\/wp-json\/wp\/v2\/journal_article\/31312"}],"collection":[{"href":"https:\/\/archivio.irpa.eu\/en\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/archivio.irpa.eu\/en\/wp-json\/wp\/v2\/types\/journal_article"}],"wp:attachment":[{"href":"https:\/\/archivio.irpa.eu\/en\/wp-json\/wp\/v2\/media?parent=31312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}